<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ahmad AM</submitter><funding>World Health Organization</funding><funding>Health Services Academy, Islamabad, Pakistan</funding><pagination>e055381</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8987211</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(4)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>This study adapted WHO's &lt;b>'&lt;/b>Unity Study' protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection.&lt;h4>Design&lt;/h4>This population-based, age-stratified cross-sectional study was conducted at the level of households (HH).&lt;h4>Participants&lt;/h4>All ages and genders were eligible for the study (exclusion criteria: contraindications to venipuncture- however, no such case was encountered). 4998 HH out of 6599 consented (1 individual per HH). The proportion of male and female study participants was similar.&lt;h4>Primary and secondary outcome measures&lt;/h4>Following were the measured outcome measures- these were different from the planned indicators (i.e. two out of the three planned indicators were measured)</pubmed_abstract><journal>BMJ open</journal><pubmed_title>COVID-19 seroprevalence in Pakistan: a cross-sectional study.</pubmed_title><pmcid>PMC8987211</pmcid><funding_grant_id>F-11-2020-WHO/DAi/HSA</funding_grant_id><pubmed_authors>Hafeez A</pubmed_authors><pubmed_authors>Masood M</pubmed_authors><pubmed_authors>Ahmad AM</pubmed_authors><pubmed_authors>Abbasi F</pubmed_authors><pubmed_authors>Shahzad K</pubmed_authors><pubmed_authors>Umar M</pubmed_authors></additional><is_claimable>false</is_claimable><name>COVID-19 seroprevalence in Pakistan: a cross-sectional study.</name><description>&lt;h4>Objectives&lt;/h4>This study adapted WHO's &lt;b>'&lt;/b>Unity Study' protocol to estimate the population prevalence of antibodies to SARS CoV-2 and risk factors for developing SARS-CoV-2 infection.&lt;h4>Design&lt;/h4>This population-based, age-stratified cross-sectional study was conducted at the level of households (HH).&lt;h4>Participants&lt;/h4>All ages and genders were eligible for the study (exclusion criteria: contraindications to venipuncture- however, no such case was encountered). 4998 HH out of 6599 consented (1 individual per HH). The proportion of male and female study participants was similar.&lt;h4>Primary and secondary outcome measures&lt;/h4>Following were the measured outcome measures- these were different from the planned indicators (i.e. two out of the three planned indicators were measured)</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-04T12:57:43.872Z</modification><creation>2025-04-04T12:57:43.872Z</creation></dates><accession>S-EPMC8987211</accession><cross_references><pubmed>35387815</pubmed><doi>10.1136/bmjopen-2021-055381</doi></cross_references></HashMap>